The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03214367




Registration number
NCT03214367
Ethics application status
Date submitted
10/07/2017
Date registered
11/07/2017
Date last updated
1/05/2020

Titles & IDs
Public title
A Study of LY900014 in Participants With Type 1 Diabetes
Scientific title
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro With an Open-Label Postprandial LY900014 Treatment Group, in Combination With Insulin Glargine or Insulin Degludec, in Adults With Type 1 Diabetes PRONTO-T1D
Secondary ID [1] 0 0
I8B-MC-ITRM
Secondary ID [2] 0 0
16313
Universal Trial Number (UTN)
Trial acronym
PRONTO-T1D
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Type 1 Diabetes Mellitus 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - LY900014
Treatment: Drugs - Insulin Lispro
Treatment: Drugs - Insulin Glargine
Treatment: Drugs - Insulin Degludec

Experimental: LY900014 - LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.

Active Comparator: Insulin Lispro (Humalog) - Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.

Experimental: LY900014 Postmeal (Open Label) - LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.

Experimental: LY900014 - Maximum Extended Enrollment (MEE) - LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.

Active Comparator: Insulin Lispro (Humalog)-MEE - Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.

Experimental: LY900014 Postmeal (Open Label)-MEE - LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.


Treatment: Drugs: LY900014
Administered SC

Treatment: Drugs: Insulin Lispro
Administered SC

Treatment: Drugs: Insulin Glargine
Administered SC

Treatment: Drugs: Insulin Degludec
Administered SC

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 - HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with strata (pooled country, type of basal insulin, prandial insulin dosing plan, and HbA1c stratum) and treatment as fixed effects and baseline as a covariate. The efficacy estimand included participant data when baseline and at least one post-baseline measurement were available prior to permanent discontinuation of study drug.
Timepoint [1] 0 0
Baseline, Week 26
Secondary outcome [1] 0 0
Change From Baseline in 1-hour Postprandial Glucose (PPG) Excursion During Mixed-Meal Tolerance Test (MMTT) Efficacy Estimand at Week 26 - A standardized MMTT was used to characterize postprandial glucose control following administration of the study insulin. Serum glucose measured at 1-hour timepoint after the start of meal minus fasting serum glucose. 1-hour PPG excursion during MMTT uses the ANCOVA model with strata (pooled country, type of basal insulin, prandial insulin dosing plan, and HbA1c stratum) and treatment as fixed effects and baseline as a covariate. The efficacy estimand included participant data when baseline and at least one post-baseline measurement were available prior to permanent discontinuation of study drug.
Timepoint [1] 0 0
Baseline, Week 26
Secondary outcome [2] 0 0
Change From Baseline in 2-hour PPG Excursion During MMTT Efficacy Estimand at Week 26 - A standardized MMTT was used to characterize postprandial glucose control following administration of the study insulin. Serum glucose measured at 2-hour timepoint after the start of meal minus fasting serum glucose. 2-hour PPG excursion during MMTT uses the ANCOVA model with strata (pooled country, type of basal insulin, prandial insulin dosing plan, and HbA1c stratum) and treatment as fixed effects and baseline as a covariate. The efficacy estimand included participant data when baseline and at least one post-baseline measurement were available prior to permanent discontinuation of study drug.
Timepoint [2] 0 0
Baseline, Week 26
Secondary outcome [3] 0 0
Rate of Severe Hypoglycemia at Week 26 - Severe hypoglycemia is defined as an event requiring assistance of another person to administer carbohydrate, glucagon, or other resuscitative actions. During these episodes, the participant has an altered mental status and cannot assist in his or her own care, or may be semiconscious or unconscious, or experience coma with or without seizures, and may require parenteral therapy. Rate of severe hypoglycemia events per 100 years during a defined period was calculated by total number of severe hypoglycemia episodes within the period divided by the cumulative days on treatment from all participants within a treatment group *36525.
Timepoint [3] 0 0
Baseline through Week 26
Secondary outcome [4] 0 0
Rate of Documented Symptomatic Hypoglycemia at Week 26 - Documented symptomatic hypoglycemia is an event during which typical symptoms of hypoglycemia are accompanied by blood glucose (BG) of <54 mg/dL [3.0 millimole per liter (mmol/L)]. The rate of documented symptomatic hypoglycemia was estimated by negative binomial model: number of episodes = treatment with log (treatment exposure in days/365.25) as an offset variable.
Timepoint [4] 0 0
Baseline through Week 26
Secondary outcome [5] 0 0
Change From Baseline in 1,5-Anhydroglucitol (1,5-AG) at Week 26 - 1,5-anhydroglucitol (1,5-AG) is a marker of short-term glycemic control especially postprandial hyperglycemia. 1,5-AG accurately predicts rapid changes in glycemia and is tightly associated with glucose fluctuations and postprandial glucose. LS Mean was calculated using mixed model repeated measures (MMRM) including fixed class effects of treatment, strata (pooled country, type of basal insulin, HbA1c stratum and number of prandial doses at study entry), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. The analysis included data collected prior to permanent discontinuation of study drug.
Timepoint [5] 0 0
Baseline, Week 26
Secondary outcome [6] 0 0
Change From Baseline in 10-Point Self-Monitoring Blood Glucose (SMBG) Values at Week 26 - SMBG 10-point profiles were measured at fasting, 1-hour post morning meal, 2-hours post morning meal, pre midday meal, 1-hour post midday meal, 2-hours post midday meal, pre evening meal, 1-hour post evening meal, 2-hours post evening meal, and bedtime. LS Mean was analyzed using mixed model repeated measures (MMRM) including fixed class effects of treatment, strata (pooled country, type of basal insulin, HbA1c stratum and number of prandial doses at study entry), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. The efficacy estimand included participant data when baseline and at least one post-baseline measurement prior to permanent discontinuation of study drug.
Timepoint [6] 0 0
Baseline, Week 26
Secondary outcome [7] 0 0
Change From Baseline in Insulin Dose at Week 26 - LS Mean was analyzed using mixed model repeated measures (MMRM) including fixed class effects of treatment, strata (pooled country, type of basal insulin, HbA1c stratum and number of prandial doses at study entry), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. The analysis included data prior to permanent discontinuation of study drug.
Timepoint [7] 0 0
Baseline, Week 26
Secondary outcome [8] 0 0
Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) Regimen Inconvenience Domain Score at Week 26 - ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. The questionnaire measures satisfaction from the following 5 domains: Inconvenience of Regimen, Lifestyle Flexibility, Glycemic Control, Hypoglycemic Control, and Insulin Delivery Device. Data presented are the transformed overall score on a scale of 0-100, where higher scores indicate better treatment satisfaction. LS Mean was calculated using the ANCOVA model with strata (pooled country, type of basal insulin, number of prandial doses at study entry, and HbA1c stratum), and treatment as fixed effects and baseline as covariate. The analysis included data prior to permanent discontinuation of study drug. The analysis included data prior to permanent discontinuation of study drug.
Timepoint [8] 0 0
Baseline, Week 26
Secondary outcome [9] 0 0
Change From Baseline in ITSQ Lifestyle Flexibility Domain Score at Week 26 - ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. The questionnaire measures satisfaction from the following 5 domains: Inconvenience of Regimen, Lifestyle Flexibility, Glycemic Control, Hypoglycemic Control, and Insulin Delivery Device. Data presented are the transformed overall score on a scale of 0-100, where higher scores indicate better treatment satisfaction. LS Mean was calculated using the analysis of covariance (ANCOVA) with strata (pooled country, type of basal insulin, number of prandial doses at study entry, and HbA1c stratum), and treatment as fixed effects and baseline as covariate. The analysis included data prior to permanent discontinuation of study drug. The analysis included data prior to permanent discontinuation of study drug.
Timepoint [9] 0 0
Baseline, Week 26
Secondary outcome [10] 0 0
Percentage of Participants With HbA1c <7% - Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
Timepoint [10] 0 0
Week 26
Secondary outcome [11] 0 0
Change From Baseline in HbA1c at Week 52 - HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
Least Squares (LS) mean was determined by MMRM model with variables of baseline, pooled country, type of basal insulin during lead-in, prandial Insulin Dosing Plan, treatment (Type III sum of squares) as fixed factors. The analysis included data prior to permanent discontinuation of study drug.
Timepoint [11] 0 0
Baseline, Week 52

Eligibility
Key inclusion criteria
- Have T1D for at least 1 year prior to screening and continuously using insulin for at
least 1 year.

- HbA1c of =7.0 and =9.5%.

- Use insulin lispro, insulin aspart, or insulin glulisine as prandial insulin.

- Use insulin glargine, insulin detemir, insulin degludec, or neutral protamine Hagedorn
(NPH) insulin as basal insulin.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Have used other antihyperglycemic medications or therapies (inhaled, oral or
injectable) within 90-days of screening.

- Have had more than 1 severe hypoglycemic episode within 6 months of screening.

- Have had more than 1 hospitalization related to hyperglycemia or diabetic ketoacidosis
within 6 months of screening.

- Have clinically significant gastrointestinal disease.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician. - Box Hill
Recruitment hospital [2] 0 0
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician. - Geelong
Recruitment hospital [3] 0 0
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician. - Merewether
Recruitment hospital [4] 0 0
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician. - Oaklands Park
Recruitment postcode(s) [1] 0 0
3128 - Box Hill
Recruitment postcode(s) [2] 0 0
3220 - Geelong
Recruitment postcode(s) [3] 0 0
2291 - Merewether
Recruitment postcode(s) [4] 0 0
5046 - Oaklands Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Hawaii
Country [7] 0 0
United States of America
State/province [7] 0 0
Idaho
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Nevada
Country [14] 0 0
United States of America
State/province [14] 0 0
New Hampshire
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
Rhode Island
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Utah
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
Argentina
State/province [24] 0 0
Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Caba
Country [26] 0 0
Argentina
State/province [26] 0 0
Ciudad Autonoma de Buenos Aire
Country [27] 0 0
Argentina
State/province [27] 0 0
Córdoba
Country [28] 0 0
Argentina
State/province [28] 0 0
Mar del Plata
Country [29] 0 0
Austria
State/province [29] 0 0
Graz
Country [30] 0 0
Austria
State/province [30] 0 0
Wien
Country [31] 0 0
Brazil
State/province [31] 0 0
São Paulo
Country [32] 0 0
Germany
State/province [32] 0 0
Bad Mergentheim
Country [33] 0 0
Germany
State/province [33] 0 0
Falkensee
Country [34] 0 0
Germany
State/province [34] 0 0
Hamburg
Country [35] 0 0
Germany
State/province [35] 0 0
Hessen
Country [36] 0 0
Germany
State/province [36] 0 0
Magdeburg
Country [37] 0 0
Germany
State/province [37] 0 0
Mayen
Country [38] 0 0
Germany
State/province [38] 0 0
Münster
Country [39] 0 0
Germany
State/province [39] 0 0
Oldenburg
Country [40] 0 0
Germany
State/province [40] 0 0
Rheine
Country [41] 0 0
Germany
State/province [41] 0 0
Saterland
Country [42] 0 0
Greece
State/province [42] 0 0
Ampelókipoi
Country [43] 0 0
Greece
State/province [43] 0 0
Athens
Country [44] 0 0
Greece
State/province [44] 0 0
Lárisa
Country [45] 0 0
Greece
State/province [45] 0 0
Thessaloníki
Country [46] 0 0
Greece
State/province [46] 0 0
Thérmi
Country [47] 0 0
India
State/province [47] 0 0
Ahmedabad
Country [48] 0 0
India
State/province [48] 0 0
Hyderabad
Country [49] 0 0
India
State/province [49] 0 0
Indore
Country [50] 0 0
India
State/province [50] 0 0
Pune
Country [51] 0 0
India
State/province [51] 0 0
Secunderabad
Country [52] 0 0
India
State/province [52] 0 0
Visakhapatnam
Country [53] 0 0
Italy
State/province [53] 0 0
Milano
Country [54] 0 0
Italy
State/province [54] 0 0
Ravenna
Country [55] 0 0
Italy
State/province [55] 0 0
Roma
Country [56] 0 0
Italy
State/province [56] 0 0
Siena
Country [57] 0 0
Japan
State/province [57] 0 0
Amagasaki
Country [58] 0 0
Japan
State/province [58] 0 0
Fukuoka
Country [59] 0 0
Japan
State/province [59] 0 0
Kamakura
Country [60] 0 0
Japan
State/province [60] 0 0
Kanagawa
Country [61] 0 0
Japan
State/province [61] 0 0
Kumamoto
Country [62] 0 0
Japan
State/province [62] 0 0
Miyazaki
Country [63] 0 0
Japan
State/province [63] 0 0
Naka
Country [64] 0 0
Japan
State/province [64] 0 0
Sapporo
Country [65] 0 0
Japan
State/province [65] 0 0
Sasebo
Country [66] 0 0
Japan
State/province [66] 0 0
Shinjuku
Country [67] 0 0
Japan
State/province [67] 0 0
Tokyo
Country [68] 0 0
Japan
State/province [68] 0 0
Oita
Country [69] 0 0
Japan
State/province [69] 0 0
Osaka
Country [70] 0 0
Mexico
State/province [70] 0 0
Guadalajara
Country [71] 0 0
Mexico
State/province [71] 0 0
Monterrey
Country [72] 0 0
Mexico
State/province [72] 0 0
Zapopan
Country [73] 0 0
New Zealand
State/province [73] 0 0
Auckland
Country [74] 0 0
New Zealand
State/province [74] 0 0
Christchurch
Country [75] 0 0
New Zealand
State/province [75] 0 0
Wellington
Country [76] 0 0
Poland
State/province [76] 0 0
Gdansk
Country [77] 0 0
Poland
State/province [77] 0 0
Kraków
Country [78] 0 0
Poland
State/province [78] 0 0
Lublin
Country [79] 0 0
Poland
State/province [79] 0 0
Ruda Slaska
Country [80] 0 0
Poland
State/province [80] 0 0
Szczecin
Country [81] 0 0
Poland
State/province [81] 0 0
Warsaw
Country [82] 0 0
Poland
State/province [82] 0 0
Warszawa
Country [83] 0 0
Poland
State/province [83] 0 0
Wroclaw
Country [84] 0 0
Poland
State/province [84] 0 0
Lódz
Country [85] 0 0
Puerto Rico
State/province [85] 0 0
Bayamon
Country [86] 0 0
Puerto Rico
State/province [86] 0 0
Manati
Country [87] 0 0
Puerto Rico
State/province [87] 0 0
San Juan
Country [88] 0 0
Puerto Rico
State/province [88] 0 0
Yabucoa
Country [89] 0 0
Romania
State/province [89] 0 0
Bacau
Country [90] 0 0
Romania
State/province [90] 0 0
Brasov
Country [91] 0 0
Romania
State/province [91] 0 0
Bucuresti
Country [92] 0 0
Romania
State/province [92] 0 0
Lasi
Country [93] 0 0
Romania
State/province [93] 0 0
Oradea
Country [94] 0 0
Romania
State/province [94] 0 0
Ploiesti
Country [95] 0 0
Romania
State/province [95] 0 0
Satu Mare
Country [96] 0 0
Romania
State/province [96] 0 0
Timisoara
Country [97] 0 0
Romania
State/province [97] 0 0
Târgu-Mures
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Arkhangel'sk
Country [99] 0 0
Russian Federation
State/province [99] 0 0
Kursk
Country [100] 0 0
Russian Federation
State/province [100] 0 0
Moscow
Country [101] 0 0
Russian Federation
State/province [101] 0 0
Saint Petersburg
Country [102] 0 0
Russian Federation
State/province [102] 0 0
Saratov
Country [103] 0 0
Slovakia
State/province [103] 0 0
Košice
Country [104] 0 0
Slovakia
State/province [104] 0 0
Malacky
Country [105] 0 0
Slovakia
State/province [105] 0 0
Nové Mesto nad Váhom
Country [106] 0 0
Slovakia
State/province [106] 0 0
Rožnava
Country [107] 0 0
Spain
State/province [107] 0 0
Barcelona
Country [108] 0 0
Spain
State/province [108] 0 0
Valencia
Country [109] 0 0
Spain
State/province [109] 0 0
Málaga
Country [110] 0 0
Spain
State/province [110] 0 0
Sevilla
Country [111] 0 0
Spain
State/province [111] 0 0
Teruel
Country [112] 0 0
Sweden
State/province [112] 0 0
Göteborg
Country [113] 0 0
Sweden
State/province [113] 0 0
Linköping
Country [114] 0 0
Sweden
State/province [114] 0 0
Lund
Country [115] 0 0
Sweden
State/province [115] 0 0
Stockholm
Country [116] 0 0
Taiwan
State/province [116] 0 0
Chang-hua
Country [117] 0 0
Taiwan
State/province [117] 0 0
Taichung
Country [118] 0 0
Taiwan
State/province [118] 0 0
Tainan
Country [119] 0 0
Taiwan
State/province [119] 0 0
Taipei
Country [120] 0 0
Taiwan
State/province [120] 0 0
Yongkang

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The main purpose of this study is to evaluate the efficacy of the study drug LY900014
compared to insulin lispro, both in combination with insulin glargine or insulin degludec, in
adults with type 1 diabetes (T1D).
Trial website
https://clinicaltrials.gov/show/NCT03214367
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications